Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Tumor lysis syndrome associated with weekly paclitaxel treatment in a case with ovarian cancer.

Yahata T, Nishikawa N, Aoki Y, Tanaka K

Department of Obstetrics and Gynecology, Niigata University School of Medicine, 1-757 Asahimachi-Dori, Niigata, Japan. yahatat@med.niigata-u.ac.jp

BACKGROUND: Tumor lysis syndrome (TLS) is characterized by biochemical changes such as hyperuricemia and hyperkalemia due to rapid tumor lysis of malignant cells, usually after chemotherapy. TLS is a rare complication in nonhematological malignancies. CASE: A 53-year-old female received intravenous weekly paclitaxel for recurrent ovarian cancer with massive ascites. Five days following the administration of paclitaxel, the patient developed TLS. She responded well to appropriate treatment with a combination of vigorous intravenous hydration, furosemide, allopurinol, and sodium bicarbonate. CONCLUSION: This case report describes the first patient to develop TLS following paclitaxel administration for ovarian cancer. Our case is extremely exceptional because TLS occurred after the low dosage administration of paclitaxel for relatively insensitive tumor types without any risk factors.

Published 27 October 2006 in Gynecol Oncol, 103(2): 752-4.
Full-text of this article is available online (may require subscription).

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.